{"id":"lamotrigine-generic-a","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"10-20","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL741","moleculeType":"Small molecule","molecularWeight":"256.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents the repetitive firing of action potentials. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:33.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial seizures)"},{"name":"Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes)"}]},"trialDetails":[{"nctId":"NCT01995825","phase":"PHASE4","title":"Lamotrigine Bioequivalence","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02821338","phase":"PHASE1","title":"A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2016-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT04015687","phase":"PHASE1","title":"A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-07-15","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT01733394","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-12-12","conditions":"Epilepsy","enrollment":54},{"nctId":"NCT01713777","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-04","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":307029,"reaction":"DRUG INEFFECTIVE"},{"count":236904,"reaction":"OFF LABEL USE"},{"count":198748,"reaction":"NAUSEA"},{"count":195886,"reaction":"FATIGUE"},{"count":177794,"reaction":"DIARRHOEA"},{"count":167404,"reaction":"DYSPNOEA"},{"count":149814,"reaction":"HEADACHE"},{"count":144153,"reaction":"PAIN"},{"count":128177,"reaction":"VOMITING"},{"count":126185,"reaction":"DIZZINESS"}],"_approvalHistory":[{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20170106","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20101223","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20091014","type":"ORIG","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20230829","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240813","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240501","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20200915","type":"ORIG","sponsor":"AVET","applicationNumber":"ANDA205360"},{"date":"20130116","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20041001","type":"ORIG","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20250822","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20101230","type":"SUPPL","sponsor":"FOUGERA PHARMS INC","applicationNumber":"NDA021735"},{"date":"20190705","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20101110","type":"ORIG","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20150608","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20141215","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20111129","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20111129","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20190705","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20190118","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20150209","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20130107","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20240227","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"},{"date":"20250325","type":"SUPPL","sponsor":"THERATECHNOLOGIES","applicationNumber":"BLA022505"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lamotrigine Generic \"A\"","genericName":"Lamotrigine Generic \"A\"","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive therapy for partial seizures), Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}